Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Stock Short Interest Climbs 60.0%

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) saw a large growth in short interest in September. As of September 15th, there was short interest totaling 9,061 shares, a growth of 60.0% from the August 31st total of 5,662 shares. Based on an average daily volume of 18,160 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the shares of the company are short sold.

Cryo-Cell International Price Performance

Shares of CCEL stock traded up $0.15 during trading hours on Wednesday, reaching $4.20. 2,160 shares of the company’s stock were exchanged, compared to its average volume of 12,989. The company’s 50 day moving average is $3.97 and its two-hundred day moving average is $3.66. The company has a market cap of $33.85 million, a P/E ratio of -14.00 and a beta of 0.47. Cryo-Cell International has a 1 year low of $2.72 and a 1 year high of $4.90.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share for the quarter. The business had revenue of $7.78 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP increased its stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,064 shares of the company’s stock after purchasing an additional 4,046 shares during the quarter. Susquehanna International Group LLP owned 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a biotechnology and healthcare services company focused on the collection, processing, testing and long-term storage of umbilical cord blood and cord tissue. The company provides families with access to private stem cell banking services intended to preserve potentially valuable biological material for future medical use.

Its services generally include coordinating the collection of cord blood and tissue at birth, transporting specimens to its processing facilities, isolating and cryopreserving stem cells, and maintaining the stored materials under controlled conditions.